Drug General Information
Drug ID
D00OTT
Former ID
DNC001810
Drug Name
ISIS 1570
Drug Type
Antisense drug
Indication Pouchitis [ICD10:K91.8] Approved [551871]
Company
Isis Pharmaceuticals
Target and Pathway
Target(s) mRNA of Intercellularadhesion molecule-1 Target Info [549645]
KEGG Pathway NF-kappa B signaling pathway
Cell adhesion molecules (CAMs)
Natural killer cell mediated cytotoxicity
TNF signaling pathway
Leukocyte transendothelial migration
African trypanosomiasis
Malaria
Staphylococcus aureus infection
Influenza A
HTLV-I infection
Epstein-Barr virus infection
Rheumatoid arthritis
Viral myocarditis
NetPath Pathway IL5 Signaling Pathway
IL1 Signaling Pathway
TSH Signaling Pathway
IL6 Signaling Pathway
IL2 Signaling Pathway
ID Signaling Pathway
TWEAK Signaling Pathway
RANKL Signaling Pathway
TNFalpha Signaling Pathway
Pathway Interaction Database Thromboxane A2 receptor signaling
Glucocorticoid receptor regulatory network
amb2 Integrin signaling
Beta2 integrin cell surface interactions
Reactome Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Integrin cell surface interactions
Interferon gamma signaling
WikiPathways Type II interferon signaling (IFNG)
IL1 and megakaryotyces in obesity
Human Complement System
Spinal Cord Injury
Interleukin-11 Signaling Pathway
RANKL/RANK Signaling Pathway
Integrin cell surface interactions
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell
Folate Metabolism
Vitamin B12 Metabolism
Selenium Micronutrient Network
References
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 549645US patent application no. 6,300,491, Oligonucleotide inhibition of cell adhesion.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.